Startups
CMTA supports the development of new treatments for CMT, improvements in the quality of life for people with CMT, and efforts to find a cure.
Overview
Location
United States, Pennsylvania, Glenolden
Mentions in press and media 27
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 12, 2026 | CMTA Honors World-Renowned Clinician Michael E. Shy, MD, with Lifetime Achievement Award | Michael E. Shy, MD Dr. Shy's decades of work have helped identify CMT genes and establish research networks, while he has cared for generations of families with CMT. It is difficult to look at CMT today and find an area Dr. Shy hasn’t ... |
| Sep 24, 2026 | CMTA Invests $110,500 to Develop Novel ASO Medicine for CMT2A | New CMTA partnership with La Jolla Labs will develop a first-of-its-kind ASO therapeutic targeting CMT2A, the most common axonal type of CMT. Targeted genetic approaches such as this are a key part of CMTA’s research strategy. This new part... |
| Sep 8, 2026 | CMTA Announces $165,000 Investment to Advance Treatments for CMT1A and CMT1E | New CMTA-funded research will study treatment timing, PMP22 activity and biomarkers to help guide future clinical trials for CMT1A and CMT1E. Every step toward better trials brings potential therapies closer to families living with CMT.” — ... |
| Sep 1, 2026 | Always tripping or spraining your ankles? When ‘clumsiness’ could be a genetic nerve disorder | Listen 10 min New: You can now listen to articles. This audio is generated by an AI tool. The odd stubbed toe, ankle sprain, missed footing when stepping up a curb… we all have our moments of clumsiness as able-bodied adults. But when those... |
| Aug 11, 2026 | CMTA Advances Drug Repurposing with an Additional $225,720 Investment in CMT1B and CMT1E Research | Maurizio D'Antonio, PhD Project extends ongoing CMTA-funded research in CMT1A that targets protein-clearance machinery to restore peripheral nerve function. This project demonstrates how CMTA-STAR unites academic researchers and indust... |
| Jun 23, 2026 | CMTA Appoints Aimee Yrlas Simpson as Chief Revenue Officer, Expanding Its Impact for People Living with CMT | Aimee Yrlas Simpson Appointment strengthens CMTA's ability to accelerate research and improve the lives of people living with Charcot-Marie-Tooth disease. Aimee brings the experience and leadership to this new role that we need to stre... |
| May 12, 2026 | Geneticist Behind the First Identified Cause of CMT Joins CMTA-STAR Scientific Advisory Board | Vincent TImmerman, PhD The geneticist who identified the first genetic cause of CMT joins CMTA-STAR's Scientific Advisory Board, bringing 30 years of CMT expertise. GLENOLDEN, PA, UNITED STATES, May 12, 2026 /EINPresswire.com/ -- Vince... |
| Mar 31, 2026 | CMTA Receives Highly Competitive $154,000 American Camp Association Grant for Its Camp Footprint Program | CMTA's Camp Footprint receives $154,000 ACA Character at Camp Grant, launches Footprint Fellowship, a two-year leadership initiative for youth living with CMT. This grant empowers us to bring the same camp magic beyond the summer for o... |
| Feb 26, 2026 | CMTA Invests $141,000 to Study Hearing and Balance to Develop Better Clinical Trial Outcome Measures in CMT | Gabriel Corfas, PhD Study examines inner-ear signaling in CMT to improve how clinical trials measure whether a treatment is working. By investing in research examining how signals from the inner ear are processed, CMTA is supporting outcome... |
Show more
Reviews 0
FAQ about Charcot
What has the press written about Charcot?
Parsers VC has collected 27 articles mentioning Charcot, among them “CMTA Honors World-Renowned Clinician Michael E. Shy, MD, with Lifetime Achievement Award” (Oct 12, 2026) and “CMTA Invests $110,500 to Develop Novel ASO Medicine for CMT2A” (Sep 24, 2026).
Is Charcot still active?
Yes, Charcot is active; its latest activity on Parsers VC dates from Oct 14, 2026.